Results 151 to 160 of about 119,911 (209)

Interplay Between Poly(ADP-ribosyl)ation and Specific Inner Cellular Events That Suggest Combination Strategies for Overcoming PARP Inhibitor Resistance. [PDF]

Pharmaceutics
Xu L, Kong X, Zhang B, Ma H, Li X, Deng Y, Liu W, Ren W, Tang X, Zhang D.   +9 more
europepmc   +1 more source

GSK3β guides chromosomal repair pathway selection to support BRCA1-independent PARP inhibitor sensitivity. [PDF]

J Clin Invest
Leung JW, Gius D.
europepmc   +1 more source

Evaluating carboplatin and PARP inhibitor combination efficacy using high-grade serous carcinoma spheroids and organoids. [PDF]

Cancer Biol Ther
Tomas EJ, Davis J, Ramos Valdes Y, Shepherd TG.   +3 more
europepmc   +1 more source

Supplemental Figure S2 from [¹⁸F]FluorThanatrace ([¹⁸F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study [PDF]

Austin R. Pantel, Sarah B. Gitto, Mehran Makvandi, Hyoung Kim, Sergey Medvedev, Joanna K. Weeks, Drew A. Torigian, Chia‐Ju Hsieh, Benjamin Ferman, Nawar Latif, János L. Tanyi, Lainie P. Martin, Shannon M. Lanzo, Fang Liu, Quy Cao, Gordon B. Mills, Robert K. Doot, David A. Mankoff, Robert H. Mach, Lilie L. Lin, Fiona Simpkins   +20 more
openalex   +1 more source

Repression of PRMT activities sensitize human homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment. [PDF]

Elife
Zhang Y, Xu M, Yuan J, Hu Z, Jiang J, Sun Y, Huang J, Wang Y, Wang B, Shen J, Long M, Fan Y, Montone KT, Tanyi J, Kim SH, Tavana O, Vonderheide RH, Chan HM, Domchek S, Zhang L, Hu X.   +20 more
europepmc   +1 more source

Use of First-Line PARP Inhibitors in Ovarian Cancer

, 2019
Ursula Hasler-Strub
openalex   +1 more source

Unmatched Cell Line Collections Are Not Optimal for Identification of PARP Inhibitor Response and Drug Synergies. [PDF]

J Cell Mol Med
Phan Z, Fernandez KJ, Caldon CE.
europepmc   +1 more source

Nitric oxide-donor/PARP-inhibitor combination: A new approach for sensitization to ionizing radiation

, 2019
Aaron Wilson, Vijay Menon, Zubair Khan, Asim Alam, Larisa Litovchick, Vasily A. Yakovlev   +5 more
openalex   +1 more source

Genome-wide CRISPR-Cas9 screening identifies CLK1 inhibition as a strategy to restore PARP inhibitor sensitivity via ERCC1 isoform switching. [PDF]

Protein Cell
Liu C, Xu F, Wu Y, Li J, Ni M, Xia S, Chen L, Zhao H, Yu M, Zhou Y, Zhang M, Li J, Wu X, Huang Y, Zhu T, Chen X.   +15 more
europepmc   +1 more source